Gufic Biosciences share news, announcements and annual reports
NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap
Gufic Biosciences Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹418.80down ₹4.95 (1.17%)BSE ₹420.40
Share price at the NSE close on 29 Oct 2026. Previous close ₹423.75.
29 Oct: open ₹423.00, high ₹424.05, low ₹416.25
52-week range of traded prices to 29 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,200 Cr959th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 57.17
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.32
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.02%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 26,73756.8% delivered
Gufic Biosciences share news and announcements
608 announcements, routine notices left out, newest first. Page 7 of 13.
Jul 2020
3 Jul · Business
May 2020
12 May · Updates
Apr 2020
16 Apr · Business
10 Apr · Legal
The exchange asked on 9 Apr 2020
Feb 2020
13 Feb · Board meeting
13 Feb · Results
Dec 2019
20 Dec · Related Party Transactions
3 Dec · Results
2 Dec · Updates
2 Dec · Updates
Nov 2019
21 Nov · Board meeting
14 Nov · Board meeting Cancelled
5 Nov · Corporate Insolvency Resolution Process
Oct 2019
Sep 2019
7 Sep · Corrigendum
Aug 2019
14 Aug · Board meeting
13 Aug · Management
13 Aug · Management
13 Aug · Board meeting
13 Aug · Results
6 Aug · Board meeting
Jul 2019
1 Jul · Related Party Transactions
Jun 2019
29 Jun · Board meeting
15 Jun · Statement on Impact of Audit Qualifications
13 Jun · Results
4 Jun · Legal
Exchange has sought clarification from Gufic Biosciences Limited with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
May 2019
23 May · Board meeting
Apr 2019